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Pathway-based analysis for genome-wide
association study data of bipolar disorder
provides new insights for genetic study
Dear Editor,
Bipolar disorder (BD) is an episodic recurrent pathological
mood disturbance with estimated heritability ranging from
80%–85% (Barnett and Smoller, 2009). Although many
studies have indicated that BD is a polygenic disease inﬂu-
enced by many genes with small effect, the pathogenesis of
BD is still not well understood. According to the catalog of
published genome-wide association studies (GWAS) (Welter
et al., 2014), there have been 31 BD GWASs (including
bipolar disorder related symptoms and combined GWAS with
other related disorders) till 01/15/2015, including the largest
BD GWAS from the Psychiatric Genomics Consortium (PGC)
(Sklar et al., 2011). But these GWAS analyses mainly
focused on single SNP/gene and only identiﬁed a number of
signiﬁcant SNPs that account for a small proportion of the
genetic variants. To detect the association between pathway
and trait for further GWAS data interpretation and mechanism
study, pathway-based analysis (PBA) has been introduced to
analyze GWAS data (Wang et al., 2010).
Comparing with traditional genetic association analyses,
PBA can detect the additive effects of multiple minor genes. It
has been proved to be a feasible solution to interpret GWAS
result and promote the analytical level from SNP/gene to
pathway. In recent years, a number of PBA methods have
been developed whose null hypothesis being tested can be
broadly classiﬁed as ‘self-contained’ versus ‘competitive’
based on whether comparisons were made between genes
in a speciﬁc pathway and non-associated genes or other
genes in the genome. Additionally, the input data of these
statistical methods can be broadly classiﬁed into two types:
SNP P-values and raw genotype (Wang et al., 2010).
Among the several published PBA studies for BD (as
collected in BDgene (Chang et al., 2013)), the majority of the
data sources focused on the Wellcome Trust Case Control
Consortium (WTCCC) data (Wellcome Trust Case Control
2007), which was published several years ago. The large
scale of PGC data has been used in two PBA studies
(Duncan et al., 2014; Yu et al., 2014a), but they are both
hypothesis-based and only focus on one type of pathway
instead of all pathways. In addition, using more than one
PBA tools to get the consistent result has become more
popular (Duncan et al., 2014) although most of the early
studies only used one. By now, the results of published PBA
studies are still of low repeatability and need further repli-
cation. Hence, it is necessary to further analyze the large
scale of GWAS data from PGC by using PBA methods to get
more reliable disease related pathways.
In this study, we analyzed six BD GWAS datasets from
PGC (Sklar et al., 2011) by merging them into two groups
according to the platform. The same quality control (QC)
process was conducted for both groups of data by using
PLINK (see supplementary material for detail). After QC, the
two groups of datasets contained 4568 cases and 6255
controls in total, and the numbers of overlapped SNPs were
276,592 in Group A and 477,624 in Group B separately (as
shown in Table S1). We used three tools (i-GSEA4GWAS v2
(Zhang et al., 2014), SNP Ration Test (SRT) (O’Dushlaine
et al., 2009) and GenGen (Wang et al., 2007)) for our anal-
ysis. The brief introduction and parameter selection about
these three tools were described in supplementary material.
The pathway-based analysis results for two groups of
GWAS datasets by three PBA tools were summarized in
Table 1. By inputting SNP P-value list, i-GSEA4GWAS v2
generated 31 candidate pathways for Group A and 31 can-
didate pathways for Group B, which shared 12 pathways
between Group A and Group B. The calculation of gene-set
enrichment score was similar between i-GSEA4GWAS v2
and GenGen, but GenGen used genotype data as input and
permutation was conducted at phenotype level. GenGen got
133 candidate pathways from Group B, but none from Group
A. Furthermore, SRT provided 10 candidate pathways from
Group A and 5 candidate pathways from Group B, and there
was no overlapped pathway between Group A and Group B.
Comparison among different PBA tools for the same GWAS
dataset was conducted. For Group A, i-GSEA4GWAS v2
shared four pathways with SRT; no shared pathway for either
other pairs of tools and three tools. For Group B,
i-GSEA4GWAS v2 shared 27 pathways and two pathways
with GenGen and SRT separately; GenGen and SRT shared
three pathways, in which, two pathways were shared by
three tools.
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As a result, 33 unique pathways were obtained from the
shared pathways by GWAS datasets or PBA tools. The list of
pathways and supported datasets and tools were shown in
Table 2. Among these 33 pathways, one pathway “TGF beta
signaling pathway” was validated by one PBA tool, two
pathways (“Oocyte meiosis” and “Ubiquitin mediated prote-
olysis”) were validated by all three PBA tools, other path-
ways were validated by two PBA tools. Moreover, six
pathways had FDR < 0.05 in Group A dataset and six
pathways had FDR < 0.05 in Group B dataset. Especially,
‘Retinol metabolism’ and ‘Metabolism of xenobiotics by
cytochrome P450’ had FDR < 0.05 in both Group A and
Group B datasets, which showed great possibility of corre-
lation with BD.
Our analysis also validated several pathways reported by
previous PBA studies. For example, phosphatidylinositol
signaling system and p53 signaling pathway were identiﬁed
as risk pathways by Chen et al. using a risk-scoring mea-
surement to fuse SNPs and pathways (Chen et al., 2009);
N-Glycan biosynthesis, ABC transporters and cell cycle were
identiﬁed in (Peng et al., 2010) by using hypergeometric test;
Neurotrophin signaling pathway has not been reported by
PBA of BD yet, but it has been reported by network analysis
paper for schizophrenia (Yu et al., 2014b), and neurotrophic
signaling cascades has played an important role in the
pathophysiology and treatment of bipolar disorder (Shaltiel
et al., 2007).
Besides the pathways validated by other PBA papers, we
also identiﬁed several novel pathways, which have not been
reported to be associated with bipolar disorder by PBA study
but have been validated in other literature and deserve fur-
ther attention, including ‘Ubiquitin mediated proteolysis’ and
‘Oocyte meiosis’, which were validated by three PBA tools in
our analysis and also statistical signiﬁcant in Group A
dataset (FDR < 0.05); ‘Retinol metabolism’ and ‘Metabolism
of xenobiotics by cytochrome P450’, which were identiﬁed
in both two groups with signiﬁcant association with BD
(P-value < 0.05, FDR < 0.05). Evidence for the association of
these pathways with bipolar disorder and other related psy-
chiatric disorders from literature was summarized in the
supplementary material.
In summary, compared with previous PBA studies on
BD, our analysis includes more samples and uses genotype
data to analyze all KEGG pathways. By using multiple
GWAS datasets and PBA tools, our analysis could provide
better interpretation for the GWASs of BD to further identify
disease-related mechanism. The pathways we identiﬁed
would provide new insights for the genetic and mechanism
study of BD. In particular, the novel pathways we ﬁrst
identiﬁed such as ‘Ubiquitin mediated proteolysis’, ‘Oocyte
meiosis’ and ‘Metabolism of xenobiotics by cytochrome
P450’ would provide new perspectives to the following
studies. These pathways need and also deserve further
validation and replication to explore the pathogenic mech-
anism of BD.
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Table 1. Comparison result for different groups of GWAS datasets and PBA tools
Group A Group B Overlapped among
Group A and Group B
i-GSEA4GWAS v2 31 31 12
Overlapped in GenGen 0 27
Overlapped in SRT 4 2
Overlapped in three tools 0 2
GenGen 0 133 0
Overlapped in SRT 0 3
Overlapped in i-GSEA4GWAS v2 0 27
Overlapped in three tools 0 2
SRT 10 5 0
Overlapped in GenGen 0 3
Overlapped in i-GSEA4GWAS v2 4 2
Overlapped in three tools 0 2
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Table 2. Validated pathways by two groups of GWAS datasets or at least two PBA tools









hsa00983 Drug metabolism-other enzymes Group A-Group B 0.001 (A), 0.0602 (B) 0.025 (B)
hsa00830 Retinol metabolism Group A-Group B 0.0025 (A), 0.0438 (B) 0.021 (B)
hsa00140 Steroid hormone biosynthesis Group A-Group B 0.003 (A), 0.1941 (B) 0.043 (B)
hsa00860 Porphyrin and chlorophyll metabolism Group A-Group B 0.003 (A), 0.0658 (B) 0.034 (B)
hsa00980 Metabolism of xenobiotics by
cytochrome p450
Group A-Group B 0.0077 (A), 0.0357 (B) 0.004 (B)
hsa00982 Drug metabolism - cytochrome p450 Group A-Group B 0.0264 (A), 0.1413 (B) 0.019 (B)
hsa04722 Neurotrophin signaling pathway Group A-Group B 0.0586 (A), 0.1478 (B) 0 (B)
hsa04914 Progesterone-mediated oocyte
maturation
Group A-Group B 0.0632 (A), 0.0665 (B) 0.003 (B)
hsa04350 TGF beta signaling pathway Group A-Group B 0.1426 (A), 0.1456 (B)
hsa04960 Aldosterone-regulated
sodium reabsorption
Group A-Group B 0.1501 (A), 0.1383 (B) 0.249 (B)
hsa05214 Glioma Group A-Group B 0.1507 (A), 0.1466 (B) 0.108 (B)
hsa05340 Primary immunodeﬁciency Group A-Group B 0.2111 (A), 0.2086 (B) 0.011 (A)
hsa05217 Basal cell carcinoma Group B 0.2146 (B) 0 (B)
hsa04114 Oocyte meiosis Group B 0.043 (B) 0 (B) 0.007 (B)
hsa04512 ECM-receptor interaction Group B 0.1643 (B) 0.001 (B)
hsa00510 N-glycan biosynthesis Group B 0.152 (B) 0.001 (B)
hsa05412 Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
Group B 0.2058 (B) 0.002 (B)
hsa00601 Glycosphingolipid biosynthesis
lacto and neolacto series
Group B 0.1406 (B) 0.002 (B)
hsa04540 Gap junction Group B 0.166 (B) 0.003 (B)
hsa04720 Long-term potentiation Group B 0.0482 (B) 0.003 (B)
hsa04120 Ubiquitin mediated proteolysis Group B 0.019 (B) 0.002 (B) 0.021 (B)
hsa04115 p53 signaling pathway Group B 0.109 (B) 0.003 (B)
hsa04260 Cardiac muscle contraction Group B 0.0456 (B) 0.007 (B)
hsa02010 ABC transporters Group B 0.1515 (B) 0.008 (B)
hsa00040 Pentose and glucuronate
interconversions
Group B 0.2056 (B) 0.039 (B)
hsa05219 Bladder cancer Group B 0.15 (B) 0.042 (B)
hsa03420 Nucleotide excision repair Group B 0.1332 (B) 0.046 (B)
hsa04730 Long-term depression Group B 0.1464 (B) 0.058 (B)
hsa00591 Linoleic acid metabolism Group B 0.1444 (B) 0.111 (B)
hsa04110 Cell cycle Group B 0.001 (B) 0.042 (B)
hsa04142 Lysosome Group A 0.2291 (A) 0.008 (A)
hsa04070 Phosphatidylinositol
signaling system
Group A 0.201 (A) 0.043 (A)
hsa05221 Acute myeloid leukemia Group A 0.2093 (A) 0.044 (A)
a (A) Denotes the FDR or Empirical P in Group A, (B) denotes the FDR or Empirical P in Group B. FDR < 0.05 in i-GSEA4GWAS v2 are bold.
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